May 22, 2012 | 3:58 pm

Mais Bt11


Summary of risk assessment

Opinion of the scientific panel on genetically modified organisms (GMO Panel) of the European Food Safety Authority (EFSA)
Adopted 20/04/2005
Conclusion Bt11 maize is as safe as conventional maize, and releasing Bt11 for processing and food and feed use is unlikely to cause adverse effects on human health and the environment.

 

Comparative analysis
Basis of comparison Conventional counterpart (isogenic line). No difference in the physical properties of kernels and forage could be found.
Compositional analysis Several parameters were compared, including: i.e. moisture, protein, acid detergent fibre, total digestible nutrients, minerals such as calcium, phosphorous, potassium, magnesium, zinc, manganese, copper, iron, and energy. No differences were observed.

 

Safety of food and feed
New proteins(CRY1A(b)+PAT) Comparison with known toxins: No correspondence

The results of the compositional analysis did not reveal unintended differences between Bt11 maize and non-transgenic maize. Therefore no additional subchronic toxicity studies are necessary.

Allergenicity of the new proteins(PAT+Cry1A(b)) Maize is not considered a major allergenic food. In addition the present application is for feed only and allergy is not a relevant issue for animal health.
Feeding studies Tests on laying hens, broiler chicken and dairy cows did not show signs of negative health effects.

 

Environmental safety
Surviveability Maize is highly domesticated and is not viable outside of cultivation.

Bt11 maize has no altered survival, multiplication or dissemination characteristics except in the presence of glufosinate ammonium.

Out-crossing Maize has no cross-compatible wild relatives in Europe. Out-crossing is only possible with maize in neighbouring fields.
Non-target organisms The Panel has no reason to consider that Bt11 maize will cause changes to non-target organisms that differ significantly from those caused by conventional farming.
Field trials Evaluation of field trials in France, Italy, Portugal (1994, 2005, 2003) and USA (1995-1996).